Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN stock is upgraded to buy.

Patients with atopic dermatitis experienced improvements in severity with 16 weeks of tralokinumab despite the number of ...

Astegolimab from Roche's Genentech fails phase 3 COPD trial, reflecting challenges in monoclonal antibody treatment for the ...

Roche’s IgG2 monoclonal antibody (mAb) astegolimab has yielded mixed results in chronic obstructive pulmonary disease (COPD), ...

"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for ...

Patients with moderate to severe atopic dermatitis experienced a 71% decrease in Eczema Area and Severity Index scores from baseline through 16 weeks with APG777, an anti-IL-13 antibody from Apogee ...

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Among patients with severe asthma receiving dupilumab for 12 months, 91% had a clinical response and 30% achieved clinical remission.

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

We thank Sara Osborne and colleagues for their interest in our trial.1 Ligelizumab phase 3 studies in patients with chronic spontaneous urticaria (CSU)1 were done with a study design and in ...

The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly ...

Key Takeaways The use of dupilumab for the treatment of atopic dermatitis was associated with an increased risk of psoriasis compared with other systemic agents.